This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Pharmacy benefit managers (PBMs) are a key stakeholder in the drug supply chain, functioning as intermediaries between insurance providers and pharmaceutical manufacturers. PBMs administer […] The post Pharmacy Benefit Manager Reform: What’s on the Horizon? appeared first on EMPLOYEEBENEFITS BLOG.
The poll of 26 health benefits decision-makers at large firms, carried out by The Commonwealth Fund and the EmployeeBenefits Research Institute (EBRI), found that despite rising premium and health care costs, they felt obligated to offer health insurance instead of shunting employees to exchanges. .”
The advance notice is released on an annual basis and includes proposed updates […] The post CMS Releases CY 2025 Advance Notice for Medicare Advantage and Part D appeared first on EMPLOYEEBENEFITS BLOG.
And while breakthrough biologics command most spending on autoimmune conditions, it doesn’t mean all of them are cost-effective or should be on formulary. Creating an additional tier for specialty drugs — or even for biologics and biosimilars alone — can start to help control costs.
Insulin prices have increased 600 percent over the last 20 years causing many consumers to be at risk of non-adherence due to cost. 4 Solving the Affordability Issue – Legislation Influence The Inflation Reduction Act , a spending package Congress approved in 2022, capped insulin out-of-pocketcosts at $35 for Americans with Medicare.
First, most non-grandfathered group health plans and health insurance issuers offering non-grandfathered health insurance coverage in the individual and group markets will be required to disclose personalized price and cost-sharing information to participants, beneficiaries and enrollees (or their authorized representatives).
The Consolidated Appropriations Act, 2021 (“Act”), signed by President Trump on December 27, 2020, contains several provisions affecting employeebenefits. For more information on these changes and other employeebenefit law changes, contact a member of our Labor and Employment or EmployeeBenefits Group.
We organize all of the trending information in your field so you don't have to. Join 46,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content